HFS
CCCC icon

Hantz Financial Services’s C4 Therapeutics CCCC Stock Holding History

Hantz Financial Services’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
+3
New +$7 ﹤0.01% 2473

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hantz Financial Services's CCCC Position: Q1 2026 in Review

Hantz Financial Services opened a new position in C4 Therapeutics (CCCC) in Q1 2026: 3 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2473 among its holdings.

123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Hantz Financial Services held 3 shares of C4 Therapeutics worth $0 as of Q1 2026.
  • C4 Therapeutics was a new Hantz Financial Services position in Q1 2026.
  • C4 Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #2473 holding.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.